Clearside Biomedical Reports P-I/IIa (OASIS) Clinical Trial Results of CLS-AX for the Treatment of Neovascular Age-Related Macular Degeneration
- The P-I/IIa (OASIS) trial evaluates CLS-AX where 27 patients were divided into 4 cohorts i.e., cohort 1/2/3/4 at 0.03/0.1/0.5/1.0mg
- The trial met the 1EPs in 4 dose-escalating cohorts i.e., CLS-AX was well tolerated with a positive safety profile across all time points & doses, no serious AEs & no TEAEs were reported with no dose-limiting toxicities
- In 3mos., 69% & 92% did not receive additional therapy; 73% reduction in treatment burden while interim data from the extension study in cohorts 3 & 4 showed supplemental anti-VEGF inj.-free rate up to each visit was 88% to 5mos. and 75% to 6mos., 90% reduction in treatment burden over 6mos., observable signs of biologic effect with stable mean BCVA & CST to 3 & 6mos. timepoints. The P-II trial is expected to be initiated in Q1’23
Ref: Globenewswire | Image: Clearside Biomedical
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].